# A meta-analysis of video-assisted thoracoscopic decortication versus open thoracotomy decortication for patients with empyema

# Hui Pan<sup>1,2,3\*</sup>, Jiaxi He<sup>1,2,4\*</sup>, Jianfei Shen<sup>1,2,4</sup>, Long Jiang<sup>1,2,4</sup>, Wenhua Liang<sup>1,2,4</sup>, Jianxing He<sup>1,2,4</sup>

<sup>1</sup>Department of Thoracic Surgery, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; <sup>2</sup>Guangzhou Institute of Respiratory Disease & China State Key Laboratory of Respiratory Disease, Guangzhou, China; <sup>3</sup>Research Center for Translational Medicine, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; <sup>4</sup>National Clinical Research Center for Respiratory Disease, Guangzhou, China

*Contributions:* (I) Conception and design: H Pan, J He; (II) Administrative support: J He, W Liang; (III) Provision of study materials or patients: J He, J He; (IV) Collection and assembly of data: H Pan, J He, L Jiang; (V) Data analysis and interpretation: H Pan, J He, J Shen; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

\*These authors contributed equally to this work.

*Correspondence to*: Jianxing He and Wenhua Liang. No 151, Yanjiang Rd, Guangzhou 510120, Guangdong Province, China. Email: drjianxing.he@gmail.com; hejianxing@hotmail.com; liangwh1987@163.com.

**Background:** Thoracic pleural empyema is a collection of pus within a thoracic cavity. In stage 2 (fibrinopurulent) and stage 3 (organizational), decortication is the only choice. But there is no consensus on whether to choose video-assisted thoracoscopic decortication (VATD) or open thoracotomy decortication (OTD). We sought to answer this question by performing a meta-analysis.

**Method:** Six electronic databases were searched. Primary outcomes were operative time, postoperative hospital stay, prolonged air leak, chest tube duration, relapse rate, morbidity and mortality. Review Manager (RevMan) [Computer program]. Version 5.2, 2014 was used to pool the data. Subgroup analysis and publication bias analysis were also conducted.

**Result:** The operative time [mean difference -36.89; 95% confidence interval (CI), -60.96 to -12.82; P=0.003], postoperative hospital stay (mean difference -2.41; 95% CI, -3.74 to -1.09; P=0.0004), prolonged air leak (9.7% *vs.* 17.1%; RR 0.56; 95% CI, 0.33 to 0.94; P=0.03), chest tube duration (mean difference -1.52; 95% CI, -2.55 to -0.48; P=0.004), morbidity (16.4% *vs.* 24.5%; RR 0.62; 95% CI, 0.44 to 0.88; P=0.007) and mortality (4.1% *vs.* 6.2%; RR 0.47; 95% CI, 0.26 to 0.86; P=0.01) of VATD were statistically less than the OTD. In terms of relapse rate, there was no statistical significance between two surgical approaches (7.2% *vs.* 4.2%; RRN1.28; 95% CI, 0.39 to 4.15; P=0.68).

**Conclusions:** The present study summarized and compared the clinical outcomes of VATD versus OTD for the empyema patients. The current data showed that VATD might be comparable or even better than OTD in terms of operative time, postoperative hospital stay, chest tube duration, prolonged air leak rate, morbidity and mortality. But referring to the relapse rate, there was no statistical significance. The results from analysis was subject bias because of prospective randomized studies were not selected. However, VATD could be implemented safely as first-line management for most of empyema.

Keywords: VATS; empyema; thoracotomy; decortication; debridement

Submitted Feb 17, 2017. Accepted for publication Jun 12, 2017. doi: 10.21037/jtd.2017.06.109 View this article at: http://dx.doi.org/10.21037/jtd.2017.06.109

## Introduction

Thoracic pleural empyema is a collection of pus within a naturally existing thoracic cavity. It is one of the common complications of pneumonia before antibiotic prevailing. It is mainly occurred after the spread of pulmonary infection, penetrating thoracic trauma, thoracic foreign body and postoperative pleural infection (1). Three stages in the pathophysiologic process: stage 1 (exudative) when there is an increase in pleural effusion; stage 2 (fibrinopurulent) which is pleural fluid loculation and fibrinous septa formation; stage 3 (organizational) which includes scar adhesion, thoracic space constriction and inability of lung expansion (2). The symptoms of different stages are various. In the early stage, patients mostly may have fever, chest pain and cough. However, in the final stage, the shortness of breath will be the dominant symptom. Although less empyema cases occurred recently due to the antibiotic utility, it is still associated with great morbidity and mortality (3).

Surgical treatments including chest tube drainage, thoracocentesis and decortications are considerably important for the empyema patients. For the early stage (stage 1) empyema, thoracocentesis and chest tube drainage were suitable choices. But for patients who were stage 2 or 3 and had troubles in breathing because of the lung expansion constriction, decortication is necessary (4). Referring to decortications, Chambers and colleagues published a systematic review in 2010 (5). 14 papers were selected to answer the question whether video-assisted thoracoscopic decortication (VATD) might be superior to open thoracotomy decortication (OTD) for management primary empyema. Chambers' paper was a qualitative systematic review. The conclude that VATD has superior outcomes for the treatment of persistent pleural collections. Even so, there is still no consensus on whether to choose VATD or OTD. Base on the above review, we make a quantitative systematic review to prove the conclude.

The outcomes of these surgical approaches are various. Open thoracic decortication has been considered to be most favored approach with shorter operative duration, better vision and lung re-expansion in last few decades. However, video-assisted thoracoscopic decortication, a minimally invasive approach, is praised for its less damage and sooner recovery (6-8). To address the difficulty of the surgical approaches selection, the current study analyzes the operative and long-term outcomes of VATD and OTD.

## Methods

#### Search strategy

The electronic search was performed using PubMed, Medline, Cochrane Central Register of Controlled Trial, Cochrane Database of Systematic Reviews, ACP Journal Club and Database of Abstracts of Reviews of Effects from the dates of inception to February 2017. In order to maximize the sensitivity, we combined the words "empyema" with "decortication" or "debridement" and "thoracoscop" or "VATS" and "open" or "thoracotomy" as Mesh terms or in all fields. All the articles were systematically filtered using inclusion and exclusion criteria.

## Inclusion and exclusion criteria

The eligible studies for the meta-analysis should investigate patients with empyema or pleural infection and undergone VATD or OTD. Those studies which had chest tube drainage besides VATD and OTD were also included, but only the data of VATD and OTD were extracted. All publications were limited in human species and in English language. Case reports, expert opinions, abstracts, conference presentations, guidelines and reviews were excluded in case of publication bias and data duplication. Those publications with no primary outcomes, no decortication and the studies included less than 20 patients in both treatment groups were also excluded. When encountered duplicated data, only the most novel and complete reports were included for data extraction and assessment.

## Data extraction

All the data were extracted from articles, tables, figures and supplement of the publications by two inspectors respectively and independently. Discrepancies between two reviewers were resolved by discussion and consensus with the senior investigator. The extracted data included publication characteristics, sample size, gender, empyema stage, operative duration, postoperative hospital stay, chest tube duration, prolonged air leak, morbidity, relapse and perioperative mortality.

## Statistical analysis

The meta-analysis was performed to compare the VATD and OTD by combining the reported operative duration,




Figure 1 Searching procedure of meta-analysis on video-assisted thoracoscopic decortication versus open thoracotomy decortication for patients with empyema.

postoperative hospital stay and chest tube duration in "Mean ± SD" form. In terms of prolonged air leak, morbidity, relapse and perioperative mortality, risk ratio (RR) was used as a summary statistic.  $\chi^2$  tests were conducted to assess the heterogeneity between the studies, while I<sup>2</sup> (inconsistency index) was used to estimate the variation across the studies (9,10). The I<sup>2</sup> was calculated with the formula:  $I^2 = \frac{100\% \times (Q - df)}{Q}$  in which the Q stood for a heterogeneity statistic and df was defined as the degree of freedom. The heterogeneity was defined as low (25-49%), moderate (50-74%), high (>75%). Random-effect analysis model was used to calculate the mean difference, and RR. If the heterogeneity was severe, a sensitive test or a subgroup analysis would be performed. Z-test was performed to calculate the p value, which was two-sided and defined as statistically different when P<0.05. The statistical analysis was conducted via Review Manager (RevMan) [Computer program]. Version 5.2, 2014. The publication bias was analyzed via Stata 12. It would be considered as insignificant when the p>0.05 both in egger's and begg's test (*Table S1*).

## **Results**

A total of 969 articles were identified in 6 electronic database and other additional sources. After filtered by the exclusion criteria, 27 articles were selected for a further investigation and intensive evaluation. After applied the inclusion criteria, 12 article candidates were selected for group discussion. After the discussion, a final consensus was reached that 5 articles were chosen for extraction and assessment (11-15). There was no any manual search additional relevant article (Figure 1). All of the relevant articles were observational studies (Table 1). As a result, the Newcastle-Ottawa Scale (16) was used to assess the quality of relevant studies including their selection of cases, comparability of populations and exposure. The characteristics of studies were shown (Tables 1,2) and each assessment of study quality by Newcastle-Ottawa Scale were also presented (Table S2).

All the continuous data of clinical characteristics was demonstrated in "Mean  $\pm$  SD". The raw data of one article (15) reported in "Medium and interquartile range"

#### Journal of Thoracic Disease, Vol 9, No 7 July 2017

Table 1 The characteristics of the relevant articles

Author	Veer	Ctudy pariod	Decien	Institution –	Study size		
Author	Year	Study period	Region	institution –	VATD	OTD	
Muhammad (11)	2012 2008–2010 Egypt King		King Fahad Hospital	25	24		
Angelillo Mackinlay (15)	1996	1985–1994	Argentina	Buenos Aires British Hospital	31	33	
Tong (12)	2010	1996–2006	USA	Duke University Medical Center	326	94	
Cardillo (13)	2009	1996–2006	Italy	Carlo Forlanini Hospital	185	123	
Chan (14)	2007	2001–2005	Hong Kong	Queen Mary Hospital & Prince Wales Hospital	41	36	

VATD, video-assisted thoracoscopic decortication; OTD, open thoracotomy decortication.

Table 2 The characteristics of patients who had diagnosed empyema and undergone VATD or OTD

		VAT	D			OTD	P value				
Author	Gender (M/F)	Age (years)	Staging system	1/11/111	Gender (M/F)	Age (years)	Staging system	1/11/111	Age	Stage	Gender
Muhammad (11)	19/6	31.1±8.99	Light's	0/19/6	18/6	33±8.8	Light's	0/16/8	0.459	0.474	0.758
Angelillo Mackinlay (15)	23/8	48.9±17.6	ATS	0/31/0	20/13	51.1±17.8	ATS	0/33/0	0.621	1.0	0.25
Tong (12)	238/88	55±17	ATS	NA	63/31	53±17	ATS	NA	0.4	NA	0.3
Cardillo (13)	95/90	55.8±10.6	ATS	0/118/67	79/44	57±12.9	ATS	0/85/38	0.3	0.3	0.03*
Chan (14)	33/8	46.1±14.7	ATS	0/13/28	34/2	48.6±16.0	ATS	0/30/6	0.506	0.001*	0.321

VATD, video-assisted thoracoscopic decortication; OTD, open thoracotomy decortication; ATS, American Thoracic Society; NA, not available. \*, significant different.

was converted into "Mean  $\pm$  SD" (17). One article (12) only reported the mean and p value of the clinical outcome. As a result, the standard deviation was calculated by the p value. Some clinical outcomes were demonstrated in proportion which were also converted in to dichotomous data.

#### The analysis of operative outcomes

In these studies, 918 patients who were diagnosed as pleural empyema by thoracic CT scan or thoracocentesis and had undergone decortication surgeries, including 608 patients in VATD groups and 310 patients in OTD groups. The characteristics of patients which had been demonstrated in *Table 2*. In Tong's paper (12), there was no information about the Stage. So the patients might cover all stages. The follow-up duration was at least 3–4 weeks. The prolonged air leak was one of the most common complications of decortication which was existing more than 7 days after thoracic surgeries and significantly related to the chest tube duration. The morbidity was defined as the complications within 30 days after surgeries. The morbidities which were related to empyema, postoperative pneumonia or sepsis were taken into account. The relapse was considered when no empyema residual was identified after surgical approaches and re-discovered later. Giuseppe's study was failed to report chest tube duration. As a result, only four studies were analyzed in chest tube duration outcome.

According to the data, both in VATD and OTD groups, male patients accounted for a larger proportion of all patients. But in Giuseppe's study (13), the gender constitution in two arms was significantly different. While, there were more stage 3 patients in the VATD group in Chan's study (14) which was inconsistent with others. The postoperative hospital stay [mean difference –2.41; 95% confidence interval (CI), –3.74 to –1.09; P=0.0004], prolonged air leak (9.7% vs. 17.1%; RR 0.56; 95% CI, 0.33 to 0.94; P=0.03), chest tube duration (mean difference –1.52; 95% CI, –2.55 to –0.48; P=0.004), morbidity (16.4% vs. 24.5%; RR 0.62; 95% CI, 0.44 to 0.88; P=0.007) and mortality (4.1% vs. 6.2%; RR 0.47; 95% CI, 0.26 to 0.86;

4	\	VATD OTD				Mean Difference		Mean Difference			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	Year	IV, Random, 95% Cl	
Mackinlay 1996	6.7	3	31	11.6	9.1	33	12.3%	-4.90 [-8.18, -1.62]	1996	_ <b></b>	
Chan 2007	16	6.5	41	21	14.2	36	6.1%	-5.00 [-10.05, 0.05]	2007		
Giuseppe 2009	8.6	1.8	185	10	7.8	123	32.4%	-1.40 [-2.80, 0.00]	2009		
Tong 2010	7	7.7	326	10	7.7	94	26.7%	-3.00 [-4.77, -1.23]	2010		
Muhammad 2012	7.76	4.63	25	8.87	2.59	24	22.5%	-1.11 [-3.20, 0.98]	2012		
Total (95% Cl)			608			310	100.0%	-2.41 [-3.74, -1.09]		•	
Hotorogonoity: Louis-	· n ou· c	h⊮ = ki	SR dt-	= 4 (P = 1	11.1.45	1* = 429	%o				
					0.147,					-10 -5 0 5 10	
					0.14),					-10 -5 0 5 10 Favours (VATD) Favours (OTD)	
Test for overall effect:	Z= 3.57				OTD			Mean Difference			
Test for overall effect: 3	Z= 3.57	(P = 0	).0004)						Year	Favours [VATD] Favours [OTD]	
Test for overall effect: 3 Study or Subgroup	Z= 3.57	' (P = 0	).0004)		OTD				<u>Year</u> 1996	Favours (VATD) Favours (OTD) Mean Difference	
Test for overall effect: 3 <u>Study or Subgroup</u> Mackinlay 1996	Z = 3.57 \ Mean	(P = 0 /ATD SD	).0004) Total	Mean	OTD SD	Total	Weight	IV, Random, 95% Cl		Favours (VATD) Favours (OTD) Mean Difference	
Test for overall effect: 3 <u>Study or Subgroup</u> Mackinlay 1996 Chan 2007	Z = 3.57 V Mean 4.2	(P = 0 /ATD <u>SD</u> 1.5 4.4	).0004) <u>Total</u> 31	<u>Mean</u> 6.1	OTD <u>SD</u> 2.3	<u>Total</u> 33	Weight 44.2%	IV, Random, 95% Cl -1.90 [-2.85, -0.95]	1996	Favours (VATD) Favours (OTD) Mean Difference	
Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 3 <u>Study or Subgroup</u> Mackinlay 1996 Chan 2007 Tong 2010 Muhammad 2012	Z = 3.57 <u>Nean</u> 4.2 8.5	(P = 0 /ATD <u>SD</u> 1.5 4.4 13.7	).0004) <u>Total</u> 31 41	<u>Mean</u> 6.1 7.9	OTD <u>SD</u> 2.3 5.7 10.1	<u>Total</u> 33 36	Weight 44.2% 15.7%	<b>IV, Random, 95% Cl</b> -1.90 [-2.85, -0.95] 0.60 [-1.70, 2.90]	1996 2007	Favours (VATD) Favours (OTD) Mean Difference	
Test for overall effect: 3 <u>Study or Subgroup</u> Mackinlay 1996 Chan 2007 Tong 2010	Z = 3.57 <u>Mean</u> 4.2 8.5 7	(P = 0 /ATD <u>SD</u> 1.5 4.4 13.7	).0004) <u>Total</u> 31 41 326	<u>Mean</u> 6.1 7.9 9.7	OTD <u>SD</u> 2.3 5.7 10.1	<u>Total</u> 33 36 94	Weight 44.2% 15.7% 13.5% 26.6%	V, Random, 95% Cl -1.90 [-2.85, -0.95] 0.60 [-1.70, 2.90] -2.70 [-5.23, -0.17]	1996 2007 2010	Favours (VATD) Favours (OTD) Mean Difference	
Test for overall effect: 3 <u>Study or Subgroup</u> Mackinlay 1996 Chan 2007 Tong 2010 Muhammad 2012 Total (95% CI)	Z = 3.57 Mean 4.2 8.5 7 5.72	(P = 0 <u>/ATD</u> <u>SD</u> 1.5 4.4 13.7 3.27	1.0004) <u>Total</u> 31 41 326 25 423	<u>Mean</u> 6.1 7.9 9.7 7.25	0TD <u>SD</u> 2.3 5.7 10.1 2.31	<u>Total</u> 33 36 94 24 <b>187</b>	Weight 44.2% 15.7% 13.5% 26.6% 100.0%	V, Random, 95% Cl -1.90 [-2.85, -0.95] 0.60 [-1.70, 2.90] -2.70 [-5.23, -0.17] -1.53 [-3.11, 0.05]	1996 2007 2010	Favours (VATD) Favours (OTD) Mean Difference IV, Random, 95% CI	
Test for overall effect: <b>S</b> <u>Study or Subgroup</u> Mackinlay 1996 Chan 2007 Tong 2010 Muhammad 2012	Z = 3.57 <u>Mean</u> 4.2 8.5 7 5.72 : 0.40; C	' (P = 0 /ATD SD 1.5 4.4 13.7 3.27 hi <sup>2</sup> = 4.	1.0004) <u>Total</u> 31 41 326 25 423 .64, df=	<u>Mean</u> 6.1 7.9 9.7 7.25	0TD <u>SD</u> 2.3 5.7 10.1 2.31	<u>Total</u> 33 36 94 24 <b>187</b>	Weight 44.2% 15.7% 13.5% 26.6% 100.0%	V, Random, 95% Cl -1.90 [-2.85, -0.95] 0.60 [-1.70, 2.90] -2.70 [-5.23, -0.17] -1.53 [-3.11, 0.05]	1996 2007 2010	Favours (VATD) Favours (OTD) Mean Difference	

**Figure 2** The forest plot of mean difference of postoperative hospital stay (A) and chest tube duration (B) in the empyema patients who had undergone video-assisted thoracoscopic decortication (VATD) or open thoracotomy decortication (OTD). The mean postoperative hospital stay (days) and chest tube duration (days) of each study are shown as the middle of the square, the size of the square stands for the weight, and the horizontal lines show the 95% confidence interval (CI). The summarized mean difference is presented as a diamond; the heterogeneity test result is also presented below.

P=0.01) of VATD were statistically less than the OTD. In terms of relapse rate, there was no statistical significance between two surgical approaches (7.2% vs. 4.2%; RR 1.28; 95% CI, 0.39 to 4.15; P=0.68) (*Figures 2,3*). The operative time (mean difference -36.89; 95% CI, -60.96 to -12.82; P=0.003) of VATD was also less than OTD, but the heterogeneity of it was high. Thus, the subgroup analysis was conducted. However, the heterogeneity of others was not statistically significant with P>0.05.

## Discussion

Due to the visceral and parietal pleural adhesion, the expansion of lung and the respiration movement decreased significantly. The empyema patients in stage 2 and stage 3 are mainly suffering from the shortness of breath. As a result, decortication is a suitable and effective approach for them, but the damage is severe at the same time. With the minimally invasive thoracic surgery development, VATD has been introduced to the empyema surgical treatment. Nevertheless, the effectiveness of VATD is still unclear (18,19). The present meta-analysis intends to compare VATD and OTD in different clinical outcomes and

provides evidences for surgical approach selection.

The meta-analysis demonstrated that VATD had shorter operative time than OTD patients in two subgroups. Theoretically, shorter operative time may lead to less operative complication and shorter hospital stay. It is consistent with the results that in the aspects of postoperative hospital stay and morbidity, VATD performed better than OTD. However, in the high-quality data and low-quality data subgroups, the mean differences are -56.93 and -9.63, respectively (13,15). The reason that accounts for this big gap is the unsymmetrical data collection. In Giuseppe's study (13), the OTD patients were treated from January 1996 to October 2001; the VATD patients underwent the operations from September 2000 to December 2006. While in Mackinlay's report (15), OTD was performed during 1985 to 1991 and VATD was in 1992 to 1994 period. In other studies, both surgical approaches were performed symmetrically without any time gap. According to the candidate studies, the OTD data was recorded earlier than the VATD data. It means the surgeons of these two institutes may not be familiar with the VATD techniques. They may spend more time in performing VATD than their counterparts. Moreover, the

### Journal of Thoracic Disease, Vol 9, No 7 July 2017

٨									
A	VATI		OTD			Risk Ratio			Risk Ratio
Study or Subgroup					Weight	M-H, Random, 95% Cl			M-H, Random, 95% Cl
Mackinlay 1996	0	31	0	33		Not estimable			
Chan 2007	4	41	5	36	14.3%	0.70 [0.20, 2.42]			
Giuseppe 2009	34	185	31	123	48.5%	0.73 [0.47, 1.12]			
Tong 2010	21	326	17	94	37.2%	0.36 [0.20, 0.65]			
Muhammad 2012	0	25	0	24		Not estimable	2012		
Total (95% CI)		608		310	100.0%	0.56 [0.33, 0.94]			•
Total events	59		53						
Heterogeneity: Tau² =	0.10; Chi	i <sup>2</sup> = 3.79	5, df = 2 (	P = 0.1	5); l² = 47	%		0.02	
Test for overall effect:	Z = 2.21 (	(P = 0.0	13)					0.02	Favours [VATD] Favours [OTD]
В	VATI	D	OTD			<b>Risk Ratio</b>			Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	Year		M-H, Random, 95% Cl
Mackinlay 1996	0	31	4	33	13.7%	0.12 [0.01, 2.11]	1996	←	
Chan 2007	0	41	0	36		Not estimable	2007		
Giuseppe 2009	3	185	0	123	13.1%	4.67 [0.24, 89.56]	2009		
Tong 2010	39	326	9	94	60.3%	1.25 [0.63, 2.48]	2010		
Muhammad 2012	2	25	0	24	12.9%	4.81 [0.24, 95.25]	2012		
Total (05% CI)		608		240	100.0%	4 20 10 20 4 451			
Total (95% CI)		008	40	510	100.0%	1.28 [0.39, 4.15]			
Total events	44	2 - 4 4	13 5 df - 27	0 - 0 2	s): IZ - 20	ov.			
Heterogeneity: Tau <sup>2</sup> =				P = 0.2	5), IT = 28	70		0.02	0.1 İ 10 50
Test for overall effect:	Z= 0.41 (	(P = 0.6	(6)						Favours [VATD] Favours [OTD]
С	VATI		OTD			Risk Ratio			Risk Ratio
C Study or Subgroup	Events		Events		Weight	M-H, Random, 95% Cl			Risk Ratio M-H, Random, 95% Cl
					Weight 6.7%	M-H, Random, 95% Cl 1.06 [0.29, 3.89]	1996		
<u>Study or Subgroup</u> Mackinlay 1996 Chan 2007	Events 4 6	<u>Total</u> 31 41	Events	<u>Total</u> 33 36	6.7% 10.0%	M-H, Random, 95% Cl 1.06 [0.29, 3.89] 0.88 [0.31, 2.48]	1996 2007		
<u>Study or Subgroup</u> Mackinlay 1996 Chan 2007 Giuseppe 2009	Events 4 6 34	Total 31 41 185	Events 4 6 31	Total 33 36 123	6.7% 10.0% 37.5%	<u>M-H, Random, 95% Cl</u> 1.06 [0.29, 3.89] 0.88 [0.31, 2.48] 0.73 [0.47, 1.12]	1996 2007 2009		
<u>Study or Subgroup</u> Mackinlay 1996 Chan 2007 Giuseppe 2009 Tong 2010	Events 4 6 34 56	Total 31 41 185 326	Events 4 6 31 35	Total 33 36 123 94	6.7% 10.0%	<u>M-H, Random, 95% Cl</u> 1.06 (0.29, 3.89) 0.88 (0.31, 2.48) 0.73 (0.47, 1.12) 0.46 (0.32, 0.66)	1996 2007 2009 2010		
<u>Study or Subgroup</u> Mackinlay 1996 Chan 2007 Giuseppe 2009	Events 4 6 34	Total 31 41 185	Events 4 6 31	Total 33 36 123	6.7% 10.0% 37.5%	<u>M-H, Random, 95% Cl</u> 1.06 [0.29, 3.89] 0.88 [0.31, 2.48] 0.73 [0.47, 1.12]	1996 2007 2009 2010		
<u>Study or Subgroup</u> Mackinlay 1996 Chan 2007 Giuseppe 2009 Tong 2010	Events 4 6 34 56	Total 31 41 185 326	Events 4 6 31 35	Total 33 36 123 94 24	6.7% 10.0% 37.5%	<u>M-H, Random, 95% Cl</u> 1.06 (0.29, 3.89) 0.88 (0.31, 2.48) 0.73 (0.47, 1.12) 0.46 (0.32, 0.66)	1996 2007 2009 2010		
<u>Study or Subgroup</u> Mackinlay 1996 Chan 2007 Giuseppe 2009 Tong 2010 Muhammad 2012	Events 4 6 34 56	Total 31 41 185 326 25	Events 4 6 31 35	Total 33 36 123 94 24	6.7% 10.0% 37.5% 45.8%	<u>M-H, Random, 95% Cl</u> 1.06 [0.29, 3.89] 0.88 [0.31, 2.48] 0.73 [0.47, 1.12] 0.46 [0.32, 0.66] Not estimable	1996 2007 2009 2010		
<u>Study or Subgroup</u> Mackinlay 1996 Chan 2007 Giuseppe 2009 Tong 2010 Muhammad 2012 Total (95% CI)	Events 4 6 34 56 0 100	Total 31 41 185 326 25 608	Events 4 31 35 0 76	Total 33 36 123 94 24 310	6.7% 10.0% 37.5% 45.8% <b>100.0</b> %	<u>M-H, Random, 95% Cl</u> 1.06 [0.29, 3.89] 0.88 [0.31, 2.48] 0.73 [0.47, 1.12] 0.46 [0.32, 0.66] Not estimable <b>0.62 [0.44, 0.88]</b>	1996 2007 2009 2010		M-H, Random, 95% Cl
Study or Subgroup Mackinlay 1996 Chan 2007 Giuseppe 2009 Tong 2010 Muhammad 2012 Total (95% CI) Total events	Events 4 34 56 0 100 0.04; Chi	Total 31 41 185 326 25 608 <sup>2</sup> = 4.2	Events 4 31 35 0 76 2, df = 3 (	Total 33 36 123 94 24 310	6.7% 10.0% 37.5% 45.8% <b>100.0</b> %	<u>M-H, Random, 95% Cl</u> 1.06 [0.29, 3.89] 0.88 [0.31, 2.48] 0.73 [0.47, 1.12] 0.46 [0.32, 0.66] Not estimable <b>0.62 [0.44, 0.88]</b>	1996 2007 2009 2010	+ 0.02	M-H, Random, 95% Cl
Study or Subgroup Mackinlay 1996 Chan 2007 Giuseppe 2009 Tong 2010 Muhammad 2012 Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> =	Events 4 34 56 0 100 0.04; Chi	Total 31 41 185 326 25 608 <sup>2</sup> = 4.2	Events 4 31 35 0 76 2, df = 3 (	Total 33 36 123 94 24 310	6.7% 10.0% 37.5% 45.8% <b>100.0</b> %	<u>M-H, Random, 95% Cl</u> 1.06 [0.29, 3.89] 0.88 [0.31, 2.48] 0.73 [0.47, 1.12] 0.46 [0.32, 0.66] Not estimable <b>0.62 [0.44, 0.88]</b>	1996 2007 2009 2010		M-H, Random, 95% Cl
Study or Subgroup Mackinlay 1996 Chan 2007 Giuseppe 2009 Tong 2010 Muhammad 2012 Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> =	Events 4 34 56 0 100 0.04; Chi	Total 31 41 185 326 25 608 <sup>2</sup> = 4.2: (P = 0.0	Events 4 31 35 0 76 2, df = 3 (	Total 33 36 123 94 24 <b>310</b> P = 0.2	6.7% 10.0% 37.5% 45.8% <b>100.0</b> %	<u>M-H, Random, 95% Cl</u> 1.06 [0.29, 3.89] 0.88 [0.31, 2.48] 0.73 [0.47, 1.12] 0.46 [0.32, 0.66] Not estimable <b>0.62 [0.44, 0.88]</b>	1996 2007 2009 2010		M-H, Random, 95% Cl
Study or Subgroup Mackinlay 1996 Chan 2007 Giuseppe 2009 Tong 2010 Muhammad 2012 Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = Test for overall effect:	Events 4 6 34 56 0 100 0.04; Chi Z = 2.70 (	<u>Total</u> 31 41 185 326 25 <b>608</b> i <sup>2</sup> = 4.2: (P = 0.0	Events 4 31 35 0 76 2, df = 3 ( 007) OTD	Total 33 36 123 94 24 <b>310</b> P = 0.2	6.7% 10.0% 37.5% 45.8% <b>100.0</b> % 4); I <sup>2</sup> = 29	<u>M-H, Random, 95% CI</u> 1.06 (0.29, 3.89) 0.88 (0.31, 2.48) 0.73 (0.47, 1.12) 0.46 (0.32, 0.66) Not estimable <b>0.62 [0.44, 0.88]</b>	1996 2007 2009 2010 2012	-+	M-H, Random, 95% Cl
Study or Subgroup Mackinlay 1996 Chan 2007 Giuseppe 2009 Tong 2010 Muhammad 2012 Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = Test for overall effect:	Events 4 6 34 56 0 100 0.04; Chi Z = 2.70 (	<u>Total</u> 31 41 185 326 25 <b>608</b> i <sup>2</sup> = 4.2: (P = 0.0	Events 4 31 35 0 76 2, df = 3 ( 007) OTD	Total 33 36 123 94 24 <b>310</b> P = 0.2	6.7% 10.0% 37.5% 45.8% <b>100.0</b> % 4); I <sup>2</sup> = 29	<u>M-H, Random, 95% Cl</u> 1.06 [0.29, 3.89] 0.88 [0.31, 2.48] 0.73 [0.47, 1.12] 0.46 [0.32, 0.66] Not estimable 0.62 [0.44, 0.88] % Risk Ratio	1996 2007 2009 2010 2012 Year	0.02	M-H, Random, 95% Cl
Study or Subgroup Mackinlay 1996 Chan 2007 Giuseppe 2009 Tong 2010 Muhammad 2012 Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = Test for overall effect:	Events 4 6 34 56 0 100 0.04; Chi Z = 2.70 ( VATI Events	<u>Total</u> 31 185 326 25 <b>608</b> <sup>2</sup> <sup>2</sup> = 4.2 <sup>2</sup> = 0.0 <sup>2</sup> = 0.0 D <u>Total</u>	Events 4 6 31 35 0 76 2, df = 3 ( 07) OTD Events	Total 33 36 123 94 24 310 P = 0.2 <u>Total</u>	6.7% 10.0% 37.5% 45.8% <b>100.0</b> % 4); I <sup>2</sup> = 29 <u>Weight</u>	<u>M-H, Random, 95% CI</u> 1.06 [0.29, 3.89] 0.88 [0.31, 2.48] 0.73 [0.47, 1.12] 0.46 [0.32, 0.66] Not estimable 0.62 [0.44, 0.88] % Risk Ratio <u>M-H, Random, 95% CI</u>	1996 2007 2009 2010 2012 <u>Year</u> 1996	0.02	M-H, Random, 95% Cl
Study or Subgroup Mackinlay 1996 Chan 2007 Giuseppe 2009 Tong 2010 Muhammad 2012 Total (95% Cl) Total events Heterogeneity: Tau <sup>2</sup> = Test for overall effect: D Study or Subgroup Mackinlay 1996	Events 4 6 34 56 0 100 0.04; Chi Z = 2.70 ( VATI Events 1	Total           31           41           185           326           25           608           i² = 4.2:           (P = 0.0)           D           Total           31	Events 4 6 31 35 0 76 2, df = 3 ( 007) OTD Events 1	Total 33 36 123 94 24 310 P = 0.2 P = 0.2	6.7% 10.0% 37.5% 45.8% <b>100.0</b> % 4); I <sup>2</sup> = 29 <u>Weight</u>	<u>M-H, Random, 95% CI</u> 1.06 [0.29, 3.89] 0.88 [0.31, 2.48] 0.73 [0.47, 1.12] 0.46 [0.32, 0.66] Not estimable 0.62 [0.44, 0.88] % Risk Ratio <u>M-H, Random, 95% CI</u> 1.06 [0.07, 16.29]	1996 2007 2019 2010 2012 <b>Year</b> 1996 2007	0.02	M-H, Random, 95% Cl
Study or Subgroup Mackinlay 1996 Chan 2007 Giuseppe 2009 Tong 2010 Muhammad 2012 Total (95% Cl) Total events Heterogeneity: Tau <sup>2</sup> = Test for overall effect: D Study or Subgroup Mackinlay 1996 Chan 2007	Events 4 6 34 56 0 100 0.04; Chi Z = 2.70 ( VATI Events 1 0	Total           31           41           185           326           25           608           i² = 4.2:           (P = 0.0)           D           Total           31           41	Events 4 6 31 35 0 76 2, df = 3 ( 07) OTD Events 1 0	Total 33 36 123 94 24 <b>310</b> P = 0.2 Total 33 36	6.7% 10.0% 37.5% 45.8% <b>100.0</b> % 4); I <sup>2</sup> = 29 <u>Weight</u> 4.8%	<u>M-H, Random, 95% CI</u> 1.06 [0.29, 3.89] 0.88 [0.31, 2.48] 0.73 [0.47, 1.12] 0.46 [0.32, 0.66] Not estimable <b>0.62 [0.44, 0.88]</b> % <u>Risk Ratio</u> <u>M-H, Random, 95% CI</u> 1.06 [0.07, 16.29] Not estimable	1996 2007 2010 2012 2012 <u>Year</u> 1996 2007 2009	0.02	M-H, Random, 95% Cl
Study or Subgroup Mackinlay 1996 Chan 2007 Giuseppe 2009 Tong 2010 Muhammad 2012 Total (95% Cl) Total events Heterogeneity: Tau <sup>2</sup> = Test for overall effect: D Study or Subgroup Mackinlay 1996 Chan 2007 Giuseppe 2009	Events 4 6 34 56 0 100 0.04; Chi Z = 2.70 ( VATI Events 1 0 0	Total           31           41           185           326           25           608           i² = 4.2:           (P = 0.0)           D           Total           31           41           185	Events 4 6 31 35 0 76 2, df = 3 ( 107) OTD Events 1 0 4	Total 33 36 123 94 24 <b>310</b> P = 0.2 Total 33 36 123	6.7% 10.0% 37.5% 45.8% 100.0% 4); I <sup>2</sup> = 29 <u>Weight</u> 4.8% 4.2%	<u>M-H, Random, 95% CI</u> 1.06 [0.29, 3.89] 0.88 [0.31, 2.48] 0.73 [0.47, 1.12] 0.46 [0.32, 0.66] Not estimable <b>0.62 [0.44, 0.88]</b> % Risk Ratio <u>M-H, Random, 95% CI</u> 1.06 [0.07, 16.29] Not estimable 0.07 [0.00, 1.36]	1996 2007 2010 2012 2012 <u>Year</u> 1996 2007 2009 2010	- <u>+</u> 0.02	M-H, Random, 95% Cl
Study or Subgroup Mackinlay 1996 Chan 2007 Giuseppe 2009 Tong 2010 Muhammad 2012 Total (95% Cl) Total events Heterogeneity: Tau <sup>2</sup> = Test for overall effect: D Study or Subgroup Mackinlay 1996 Chan 2007 Giuseppe 2009 Tong 2010 Muhammad 2012	Events 4 6 34 56 0 100 0.04; Chi Z = 2.70 ( VATI Events 1 0 0 24	Total           31           41           185           326           25           608           i² = 4.2:           (P = 0.0)           D           Total           31           41           185           326           25	Events 4 6 31 35 0 76 2, df = 3 ( 007) OTD Events 1 0 4 14	Total 33 36 123 94 24 <b>310</b> P = 0.2 Total 33 36 123 94 24	6.7% 10.0% 37.5% 45.8% 100.0% 4); I <sup>2</sup> = 29 <u>Weight</u> 4.8% 4.2% 91.0%	M-H, Random, 95% CI 1.06 [0.29, 3.89] 0.88 [0.31, 2.48] 0.73 [0.47, 1.12] 0.46 [0.32, 0.66] Not estimable 0.62 [0.44, 0.88] % Risk Ratio M-H, Random, 95% CI 1.06 [0.07, 16.29] Not estimable 0.07 [0.00, 1.36] 0.49 [0.27, 0.92] Not estimable	1996 2007 2010 2012 2012 <u>Year</u> 1996 2007 2009 2010	- <u>-</u>	M-H, Random, 95% Cl
Study or Subgroup Mackinlay 1996 Chan 2007 Giuseppe 2009 Tong 2010 Muhammad 2012 Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = Test for overall effect: D Study or Subgroup Mackinlay 1996 Chan 2007 Giuseppe 2009 Tong 2010 Muhammad 2012 Total (95% CI)	Events 4 6 34 56 0 100 0.04; Chi Z = 2.70 ( VATI Events 1 0 0 24 0	Total           31           41           185           326           25           608           i² = 4.2:           (P = 0.0)           D           Total           31           41           185           326	Events 4 6 31 35 0 76 2, df = 3 ( 007) 0TD Events 1 0 4 14 0	Total 33 36 123 94 24 <b>310</b> P = 0.2 Total 33 36 123 94 24	6.7% 10.0% 37.5% 45.8% 100.0% 4); I <sup>2</sup> = 29 <u>Weight</u> 4.8% 4.2%	<u>M-H, Random, 95% CI</u> 1.06 [0.29, 3.89] 0.88 [0.31, 2.48] 0.73 [0.47, 1.12] 0.46 [0.32, 0.66] Not estimable <b>0.62 [0.44, 0.88]</b> % Risk Ratio <u>M-H, Random, 95% CI</u> 1.06 [0.07, 16.29] Not estimable 0.07 [0.00, 1.36] 0.49 [0.27, 0.92]	1996 2007 2010 2012 2012 <u>Year</u> 1996 2007 2009 2010	 0.02	M-H, Random, 95% Cl
Study or Subgroup         Mackinlay 1996         Chan 2007         Giuseppe 2009         Tong 2010         Muhammad 2012         Total (95% Cl)         Total events         Heterogeneity: Tau² =         Test for overall effect:         D         Study or Subgroup         Mackinlay 1996         Chan 2007         Giuseppe 2009         Tong 2010         Muhammad 2012         Total (95% Cl)         Total events	Events 4 6 34 56 0 100 0.04; Chi Z = 2.70 ( VATI Events 1 0 0 24 0 24	Total           31           41           185           326           25           608           i² = 4.2:           (P = 0.0)           D           Total           31           41           185           326           25           608           608           608           608           608           31           41           185           326           25           608	Events 4 6 31 35 0 76 2, df = 3 ( 007) 0 70 0 0 1 0 4 14 0 19	Total 33 36 123 94 24 <b>310</b> P = 0.2 Total 33 36 123 94 24 <b>310</b>	6.7% 10.0% 37.5% 45.8% 100.0% 4); I <sup>2</sup> = 29 <u>Weight</u> 4.8% 91.0% 100.0%	M-H, Random, 95% CI 1.06 [0.29, 3.89] 0.88 [0.31, 2.48] 0.73 [0.47, 1.12] 0.46 [0.32, 0.66] Not estimable 0.62 [0.44, 0.88] % Risk Ratio M-H, Random, 95% CI 1.06 [0.07, 16.29] Not estimable 0.07 [0.00, 1.36] 0.49 [0.27, 0.92] Not estimable 0.47 [0.26, 0.86]	1996 2007 2010 2012 2012 <u>Year</u> 1996 2007 2009 2010	·	M-H, Random, 95% Cl
Study or Subgroup Mackinlay 1996 Chan 2007 Giuseppe 2009 Tong 2010 Muhammad 2012 Total (95% Cl) Total events Heterogeneity: Tau <sup>2</sup> = Test for overall effect: D Study or Subgroup Mackinlay 1996 Chan 2007 Giuseppe 2009 Tong 2010 Muhammad 2012 Total (95% Cl)	Events         4         6         34         56         0         0         0         0         24         0         0         24         0         0         24         0         0         24         0         0         24         0         25         0.00; Chi         Chi         25         0.00; Chi         0         25         0.00; Chi         0 <td>Total           31           41           185           326           25           608           i² = 4.2:           (P = 0.0)           0           Total           31           41           185           326           25           608           31           41           185           326           25           608           i² = 2.00</td> <td>Events 4 6 31 35 0 76 2, df = 3 ( 07) 0 070 Events 1 0 4 14 0 19 0, df = 2 (</td> <td>Total 33 36 123 94 24 <b>310</b> P = 0.2 Total 33 36 123 94 24 <b>310</b></td> <td>6.7% 10.0% 37.5% 45.8% 100.0% 4); I<sup>2</sup> = 29 <u>Weight</u> 4.8% 91.0% 100.0%</td> <td>M-H, Random, 95% CI 1.06 [0.29, 3.89] 0.88 [0.31, 2.48] 0.73 [0.47, 1.12] 0.46 [0.32, 0.66] Not estimable 0.62 [0.44, 0.88] % Risk Ratio M-H, Random, 95% CI 1.06 [0.07, 16.29] Not estimable 0.07 [0.00, 1.36] 0.49 [0.27, 0.92] Not estimable 0.47 [0.26, 0.86]</td> <td>1996 2007 2010 2012 2012 <u>Year</u> 1996 2007 2009 2010</td> <td>↓ 0.02 ↓</td> <td>M-H, Random, 95% Cl</td>	Total           31           41           185           326           25           608           i² = 4.2:           (P = 0.0)           0           Total           31           41           185           326           25           608           31           41           185           326           25           608           i² = 2.00	Events 4 6 31 35 0 76 2, df = 3 ( 07) 0 070 Events 1 0 4 14 0 19 0, df = 2 (	Total 33 36 123 94 24 <b>310</b> P = 0.2 Total 33 36 123 94 24 <b>310</b>	6.7% 10.0% 37.5% 45.8% 100.0% 4); I <sup>2</sup> = 29 <u>Weight</u> 4.8% 91.0% 100.0%	M-H, Random, 95% CI 1.06 [0.29, 3.89] 0.88 [0.31, 2.48] 0.73 [0.47, 1.12] 0.46 [0.32, 0.66] Not estimable 0.62 [0.44, 0.88] % Risk Ratio M-H, Random, 95% CI 1.06 [0.07, 16.29] Not estimable 0.07 [0.00, 1.36] 0.49 [0.27, 0.92] Not estimable 0.47 [0.26, 0.86]	1996 2007 2010 2012 2012 <u>Year</u> 1996 2007 2009 2010	↓ 0.02 ↓	M-H, Random, 95% Cl

**Figure 3** The forest plot of risk ratio (RR) of prolonged air leak (A), relapse (B), morbidity (C) and mortality (D) in the empyema patients who had undergone video-assisted thoracoscopic decortication (VATD) or open thoracotomy decortication (OTD). The RR of each study are shown as the middle of the square, the size of the square stands for the weight, and the horizontal lines show the 95% confidence interval (CI). The summarized mean difference is presented as a diamond; the heterogeneity test result is also presented below.

2012

Author	Conversion	Conversion rate
Muhammad (11)	2	8%
Angelillo Mackinlay (15)	3	9.7%
Tong (12)	37	11.3%
Cardillo (13)	11	5.9%
Chan (14)	0	0
Total	53	8.7%

VATD, video-assisted thoracoscopic decortication; OTD, open thoracotomy decortication.

unsymmetrical data collection may bring huge bias to the outcomes.

The prolonged air leak, which is defined as air leakage lasting more than 7 days after surgery, is the most common complication of decortication. Due to the chronic infection and fibrinopurulent pleurisy, the adhesion of visceral and parietal pleura is very solid. The priority of decortications is to separate the adhesion and release the lung. It may lead to visceral pleura damage inevitably. In both surgical approaches, chest tubes will be inserted after the operations which are used for air and residual fluid drainage (20,21). The longer chest tube duration may attribute to the longer air leakage. The duration of prolonged air leak and chest tube in VATD group is longer than the OTD group. It suggests that VATD may have less damage than OTD when separating the adhesion between visceral and parietal pleura.

Referring to morbidity and mortality, based on the current study, VATD group apparently outweighed OTD group with less morbidity or mortality. It possibly benefits from the minimally invasive approach. Besides, sepsis is the main cause of postoperative mortality. These results are consistent with other studies which have not been included (22,23). Unfortunately, the candidate articles provided no detail about other complications and causes of death.

According to the relapse rate, there was no statistically significant difference between two groups. Some people claimed that the VATD might not be as good as OTD in terms of effect. Their reasons were that the vision of VATD was narrow, thus there might be residual which had been overlooked. Based on the result, we found no difference. However, there were 53 VATD cases converted to OTD intra-operatively (*Table 3*). The average conversion rate in the present study was 8.7% ranging from 0% to 11.3%. Although the conversion rate was relatively low,

it demonstrated that OTD had advantages that VATD lacked (24). If the intercostal spaces are often too narrow, ultrasonography demonstrates an encased lung or the lung fails to expand during VATD, the patient should undergo decortication by full thoracotomy. Surgeons' learning from case to case and gained technical expertise, conversion rate declined significantly especially stage 3 cases. The present study demonstrates a lower rate of conversion to open thoracotomy as compared to previous studies, which ranged from 28% to 59% (15,25-29). Some studies claimed delayed referral and gram-negative bacteria increase the conversion thoracotomy rate (22,23). Later disease stage would intent to be treated by open surgery. Although some cases were decided to choose VATD, they might be upgraded after thoracic cavity inspection and converted to open surgery. Therefore, some conversions were not inevitable. However, no specific data of the conversion reasons was provided in the studies.

Besides, numbers of limitations have to be admitted in the current study. Firstly, some outcomes were reported in various forms in the candidate articles. In order to evaluate, the forms have to be unified. For instance, Tong et.al reported operative time in "medium and interquartile range", which might generate inaccuracies after conversion. Secondly, although the subgroup analysis has been performed, the overall and subgroup difference heterogeneity of operative time outcome is severe. Thirdly, all of the candidates are retrospective observational studies. After applying the Newcastle-Ottawa Scale, two of them had less than 5 stars which had been defined as low-quality studies. The reliability of meta-analysis might be effected by the cases bias due to the unsymmetrical data collection. The result would be more reliable when high-quality studies or multi-center randomized control trials were included. Fourth, the imbalance in patient characteristics

#### Journal of Thoracic Disease, Vol 9, No 7 July 2017

between arms cannot be adjusted for due to the lack of individual patient data. The conclusion of the analysis, therefore, suffers from an imbalance between comparator arms which may not have been observed. Finally, none of those conversion cases had been described or demonstrated in detail in the relevant studies. Otherwise, more specific analysis could have been done.

In conclusion, it can be seen from the current metaanalysis that VATD is superior to OTD in the aspects of operative time, hospital stay, prolonged air leak, chest tube duration, morbidity and mortality. Meanwhile, there is no advantage in the relapse rate. In some particular circumstances, VATD may have to convert to OTD. As our opinion, experience, and learning, conversion to an open surgery procedure should not be considered as a failure of thoracoscopy, but rather an exercise of mature surgical judgment. Moreover, limitations have to be admitted in this study. A new meta-analysis will be performed, if there are more well-designed and convincing studies.

## **Acknowledgements**

None.

## Footnote

*Conflicts of Interest:* The authors have no conflicts of interest to declare.

## References

- Moore KL, Dalley AF. Clinically oriented anatomy: instructor's resource DVD-ROM. Hagerstown, Maryland: Lippincott Williams & Wilkins. 2006.
- 2. Watkins E Jr, Fielder CR. Management of nontuberculous empyema. Surg Clin North Am 1961;41:681-93.
- 3. Hamm H, Light RW. Parapneumonic effusion and empyema. Eur Respir J 1997;10:1150-6.
- Renner H, Gabor S, Pinter H, et al. Is aggressive surgery in pleural empyema justified? Eur J Cardiothorac Surg 1998;14:117-22.
- Chambers A, Routledge T, Dunning J, et al. Is videoassisted thoracoscopic surgical decortication superior to open surgery in the management of adults with primary empyema? Interact Cardiovasc Thorac Surg 2010;11:171-7.
- 6. Cheng YJ, Wu HH, Chou SH, et al. Video-assisted thoracoscopic surgery in the treatment of chronic empyema thoracis. Surg Today 2002;32:19-25.

- Hope WW, Bolton WD, Stephenson JE. The utility and timing of surgical intervention for parapneumonic empyema in the era of video-assisted thoracoscopy. Am Surg 2005;71:512-4.
- Luh SP, Hsu GJ, Cheng-Ren C. Complicated parapneumonic effusion and empyema: pleural decortication and video-assisted thoracic surgery. Curr Infect Dis Rep 2008;10:236-40.
- Higgins J, Thompson S, Deeks J, et al. Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice. J Health Serv Res Policy 2002;7:51-61.
- 10. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58.
- Muhammad MI. Management of complicated parapneumonic effusion and empyema using different treatment modalities. Asian Cardiovasc Thorac Ann 2012;20:177-81.
- Tong BC, Hanna J, Toloza EM, et al. Outcomes of videoassisted thoracoscopic decortication. Ann Thorac Surg 2010;89:220-5.
- Cardillo G, Carleo F, Carbone L, et al. Chronic postpneumonic pleural empyema: comparative merits of thoracoscopic versus open decortication. Eur J Cardiothorac Surg 2009;36:914-8.
- Chan DT, Sihoe AD, Chan S, et al. Surgical treatment for empyema thoracis: is video-assisted thoracic surgery "better" than thoracotomy? Ann Thorac Surg 2007;84:225-31.
- Angelillo Mackinlay TA, Lyons GA, Chimondeguy DJ, et al. VATS debridement versus thoracotomy in the treatment of loculated postpneumonia empyema. Ann Thorac Surg 1996;61:1626-30.
- Wells GA, Shea BJ, O'Connell D, et al. The Newcastle– Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. Appl Eng Agric 2000;18:727-34
- Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005;5:13.
- Lawrence DR, Ohri SK, Moxon RE, et al. Thoracoscopic debridement of empyema thoracis. Ann Thorac Surg 1997;64:1448-50.
- 19. Wait MA, Sharma S, Hohn J, et al. A randomized trial of empyema therapy. Chest 1997;111:1548-51.
- 20. Cassina PC, Hauser M, Hillejan L, et al. Video-assisted thoracoscopy in the treatment of pleural empyema: stagebased management and outcome. J Thorac Cardiovasc

#### Pan et al. VATS vs. thoracotomy decortication for empyema

2014

Surg 1999;117:234-8.

- 21. Wurnig PN, Wittmer V, Pridun NS, et al. Video-assisted thoracic surgery for pleural empyema. Ann Thorac Surg 2006;81:309-13.
- 22. Lardinois D, Gock M, Pezzetta E, et al. Delayed referral and gram-negative organisms increase the conversion thoracotomy rate in patients undergoing video-assisted thoracoscopic surgery for empyema. Ann Thorac Surg 2005;79:1851-6.
- 23. Luh SP, Chou MC, Wang LS, et al. Video-assisted thoracoscopic surgery in the treatment of complicated parapneumonic effusions or empyemas: outcome of 234 patients. Chest 2005;127:1427-32.
- Solaini L, Prusciano F, Bagioni P. Video-assisted thoracic surgery in the treatment of pleural empyema. Surg Endosc 2007;21:280-4.
- 25. Waller DA, Rengarajan A. Thoracoscopic decortication: a

**Cite this article as:** Pan H, He J, Shen J, Jiang L, Liang W, He J. A meta-analysis of video-assisted thoracoscopic decortication versus open thoracotomy decortication for patients with empyema. J Thorac Dis 2017;9(7):2006-2014. doi: 10.21037/jtd.2017.06.109

role for video-assisted surgery in chronic postpneumonic pleural empyema. Ann Thorac Surg 2001;71:1813-6.

- Cassina PC, Hauser M, Hillejan L, et al. Video-assisted thoracoscopy in the treatment of pleural empyema: stagebased management and outcome. J Thorac Cardiovasc Surg 1999;117:234-8.
- Metin M, Yeginsu A, Sayar A, et al. Treatment of multiloculated empyema thoracis using minimally invasive methods. Singapore Med J 2010;51:242-6.
- 28. Shahin Y, Duffy J, Beggs D, et al. Surgical management of primary empyema of the pleural cavity: outcome of 81 patients. Interact Cardiovasc Thorac Surg 2010;10:565-7.
- Lackner RP, Hughes R, Anderson LA, et al. Videoassisted evacuation of empyema is the preferred procedure for management of pleural space infections. Am J Surg 2000;179:27-30.

# Supplementary

## Table S1 The Begg's test and Egger's test results

Outcome	Begg's test	Egger's test
Operative time	Pr>1z1=0.806	P> t =0.124
Hospital stay	Pr> z =0.221	P> t =0.167
Chest tube duration	Pr> z =0.497	P>ItI=0.348
Prolonged air leak	Pr>121=1.000	P>ItI=0.862
Relapse	Pr> z =0.089	P>ItI=0.357
Morbidity	Pr>121=0.308	P>ItI=0.211
Mortality	Pr>121=1.000	P>ItI=0.898

Table S2 The assessment of the relevant articles quality (NOS)  $% \left( \mathcal{N}_{1}^{2}\right) =\left( \mathcal{N}_{1}^{2}\right) \left( \mathcal{N}_{1}^{2}\right$ 

		Quality indication of NOS									
Author	Year		Sele	ction		C	Comparabili	Exposure			
		1	2	3	4	5A	5B	6	7	8	
Muhammad	2012	Yes	Yes	No	No	Yes	Yes	Yes	Yes	No	
Angelillo Mackinlay	1996	Yes	No	No	No	No	Yes	Yes	Yes	No	
Tong	2010	Yes	Yes	Yes	No	Yes	Yes	No	Yes	No	
Cardillo	2009	Yes	No	No	Yes	No	Yes	Yes	Yes	No	
Chan	2007	Yes	Yes	No	Yes	Yes	No	Yes	Yes	No	

NOS, Newcastle-Ottawa Scale.